Novartis Stock Price, News & Analysis (NYSE:NVS)

$87.00 0.06 (0.07 %)
(As of 01/23/2018 10:52 AM ET)
Previous Close$86.94
Today's Range$86.28 - $87.01
52-Week Range$69.53 - $87.29
Volume1.67 million shs
Average Volume1.09 million shs
Market Capitalization$226.84 billion
P/E Ratio30.96
Dividend Yield2.66%
Beta0.74

About Novartis (NYSE:NVS)

Novartis logoNovartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNYSE:NVS
CUSIPN/A
Phone+41-61-3241111

Debt

Debt-to-Equity Ratio0.32%
Current Ratio1.08%
Quick Ratio0.81%

Price-To-Earnings

Trailing P/E Ratio30.9608540925267
Forward P/E Ratio18.16
P/E Growth2.33

Sales & Book Value

Annual Sales$48.52 billion
Price / Sales4.24
Cash Flow$4.77 per share
Price / Cash18.24
Book Value$31.55 per share
Price / Book2.76

Profitability

Trailing EPS$2.81
Net Income$6.71 billion
Net Margins13.73%
Return on Equity15.77%
Return on Assets8.46%

Miscellaneous

Employees123,000
Outstanding Shares2,365,590,000

Novartis (NYSE:NVS) Frequently Asked Questions

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis announced an annual dividend on Friday, January 27th. Stockholders of record on Friday, March 3rd will be given a dividend of $2.327 per share on Friday, March 3rd. The ex-dividend date of this dividend is Wednesday, March 1st. View Novartis' Dividend History.

How will Novartis' stock buyback program work?

Novartis declared that its board has initiated a share repurchase program on Saturday, April 8th 2017, which allows the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy up to 2.9% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board believes its shares are undervalued.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) released its earnings results on Tuesday, October, 24th. The company reported $1.29 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.25 by $0.04. The company had revenue of $12.41 billion for the quarter, compared to analysts' expectations of $12.21 billion. Novartis had a return on equity of 15.77% and a net margin of 13.73%. The firm's quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.23 earnings per share. View Novartis' Earnings History.

When will Novartis make its next earnings announcement?

Novartis is scheduled to release their next quarterly earnings announcement on Wednesday, January, 24th 2018. View Earnings Estimates for Novartis.

Where is Novartis' stock going? Where will Novartis' stock price be in 2018?

13 analysts have issued 12 month target prices for Novartis' shares. Their predictions range from $74.37 to $91.00. On average, they expect Novartis' share price to reach $84.41 in the next year. View Analyst Ratings for Novartis.

Are investors shorting Novartis?

Novartis saw a decrease in short interest in December. As of December 15th, there was short interest totalling 1,766,090 shares, a decrease of 36.6% from the November 30th total of 2,783,787 shares. Based on an average daily trading volume, of 1,032,386 shares, the days-to-cover ratio is currently 1.7 days.

Who are some of Novartis' key competitors?

Who are Novartis' key executives?

Novartis' management team includes the folowing people:

  • Joseph S. Jimenez, Chief Executive Officer, Member of the Executive Committee (Age 57)
  • Harry Kirsch, Chief Financial Officer, Member of the Executive Committee (Age 51)
  • Michael Ball, Chief Executive Officer of Alcon, Member of the Executive Committee
  • James Bradner M.D., President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
  • Richard D. Francis, Chief Executive Officer of Sandoz Division, Member of the Executive Committee (Age 48)
  • Paul Hudson, Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee
  • Felix R. Ehrat Ph.D., Group General Counsel, Member of the Executive Committee (Age 60)
  • Steven Baert, Head of Human Resources, Member of the Executive Committee (Age 42)
  • Vasant Narasimhan M.D., Chief Executive Officer, Member of the Executive Committee
  • Andre Wyss, Member of the Executive Committee, President of Novartis Business Services and Country President for Switzerland (Age 48)

Who owns Novartis stock?

Novartis' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include CGOV Asset Management (0.04%), Bristol John W & Co. Inc. NY (0.04%), Bartlett & Co. LLC (0.02%), Country Trust Bank (0.02%), Chevy Chase Trust Holdings Inc. (0.02%) and Confluence Investment Management LLC (0.01%). Company insiders that own Novartis stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis.

Who sold Novartis stock? Who is selling Novartis stock?

Novartis' stock was sold by a variety of institutional investors in the last quarter, including Bristol John W & Co. Inc. NY, Chickasaw Capital Management LLC, Bank of Montreal Can, Country Trust Bank, World Asset Management Inc, Country Club Trust Company n.a., New England Research & Management Inc. and Patten & Patten Inc. TN. View Insider Buying and Selling for Novartis.

Who bought Novartis stock? Who is buying Novartis stock?

Novartis' stock was bought by a variety of institutional investors in the last quarter, including McCollum Christoferson Group LLC, Chevy Chase Trust Holdings Inc., Heritage Way Advisors LLC, CGOV Asset Management, Smithbridge Asset Management Inc. DE, Thompson Rubinstein Investment Management Inc. OR, KCS Wealth Advisory and Bredin Investment LLC. Company insiders that have bought Novartis stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis.

How do I buy Novartis stock?

Shares of Novartis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novartis' stock price today?

One share of Novartis stock can currently be purchased for approximately $87.64.

How big of a company is Novartis?

Novartis has a market capitalization of $226.84 billion and generates $48.52 billion in revenue each year. The company earns $6.71 billion in net income (profit) each year or $2.81 on an earnings per share basis. Novartis employs 123,000 workers across the globe.

How can I contact Novartis?

Novartis' mailing address is Lichtstrasse 35, BASEL, 4056, Switzerland. The company can be reached via phone at +41-61-3241111 or via email at [email protected]


MarketBeat Community Rating for Novartis (NVS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  293 (Vote Outperform)
Underperform Votes:  354 (Vote Underperform)
Total Votes:  647
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Novartis (NYSE:NVS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.082.27
Ratings Breakdown: 4 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
7 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $84.41$84.41$84.52$82.27
Price Target Upside: 2.85% downside0.67% upside1.68% upside2.29% downside

Novartis (NYSE:NVS) Consensus Price Target History

Price Target History for Novartis (NYSE:NVS)

Novartis (NYSE:NVS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2018JPMorgan Chase & Co.Reiterated RatingNeutralLowView Rating Details
1/2/2018Nord/LBReiterated RatingNeutralMediumView Rating Details
12/6/2017Bank of AmericaDowngradeNeutral -> UnderperformLowView Rating Details
10/25/2017BarclaysDowngradeEqual Weight -> UnderweightN/AView Rating Details
10/23/2017Leerink SwannBoost Price TargetMarket Perform$89.00 -> $91.00N/AView Rating Details
8/9/2017CowenSet Price TargetHold$90.00MediumView Rating Details
7/26/2017Morgan StanleyUpgradeUnderweight -> OverweightLowView Rating Details
7/5/2017Credit Suisse GroupDowngradeNeutral -> Underperform$82.25MediumView Rating Details
3/22/2017Goldman Sachs GroupReiterated RatingNeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
3/7/2017Societe GeneraleUpgradeHold -> Buy$73.82 -> $74.37N/AView Rating Details
3/7/2017BNP ParibasDowngradeNeutral -> UnderperformN/AView Rating Details
1/31/2017ArgusUpgradeHold -> BuyN/AView Rating Details
1/17/2017Berenberg BankDowngradeBuy -> HoldN/AView Rating Details
1/9/2017Deutsche BankReiterated RatingNeutralN/AView Rating Details
10/16/2016Jefferies GroupReiterated RatingBuyN/AView Rating Details
10/10/2016Chardan CapitalLower Price TargetBuy$95.00 -> $92.00N/AView Rating Details
5/24/2016CitigroupReiterated RatingNeutralN/AView Rating Details
(Data available from 1/23/2016 forward)

Earnings

Novartis (NYSE:NVS) Earnings History and Estimates Chart

Earnings by Quarter for Novartis (NYSE:NVS)

Novartis (NYSE NVS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/24/2018$1.16N/AView Earnings Details
10/24/20179/30/2017$1.25$1.29$12.21 billion$12.41 billionViewN/AView Earnings Details
7/18/2017Q2 17$1.16$1.22$12.20 billion$12.24 billionViewN/AView Earnings Details
4/25/20173/31/2017$1.10$1.13$11.59 billion$11.54 billionViewN/AView Earnings Details
1/25/2017Q416$1.12$1.12$12.44 billion$12.32 billionViewN/AView Earnings Details
10/25/2016Q316$1.19$1.23$12.24 billion$12.13 billionViewListenView Earnings Details
7/19/2016Q216$1.18$1.23$12.33 billion$12.47 billionViewListenView Earnings Details
4/21/2016Q116$1.18$1.17$11.90 billion$11.60 billionViewListenView Earnings Details
1/27/2016Q415$1.18$1.14$12.64 billion$12.52 billionViewListenView Earnings Details
10/27/2015Q315$1.31$1.27$12.66 billion$12.30 billionViewListenView Earnings Details
7/21/2015Q215$1.20$1.27$12.45 billion$12.70 billionViewListenView Earnings Details
4/23/2015Q115$1.12$1.33$12.90 million$11.94 billionViewN/AView Earnings Details
1/27/2015Q314$1.13$1.21$14.68 billion$14.63 billionViewN/AView Earnings Details
10/28/2014Q3 2014$1.29$1.28$14.14 billion$14.70 billionViewN/AView Earnings Details
7/17/2014Q214$1.36$1.36$14.83 billion$14.64 billionViewN/AView Earnings Details
4/24/2014Q1 2014$1.33$1.31$14.25 billion$14.02 billionViewN/AView Earnings Details
1/29/2014Q413$1.27$1.20$15.16 billion$15.08 billionViewN/AView Earnings Details
10/22/2013Q313$1.31$1.26$14.28 billion$14.34 billionViewN/AView Earnings Details
7/17/2013Q213$1.29$1.30$14.39 billion$14.50 billionViewN/AView Earnings Details
4/24/2013Q113$1.28$1.32$14.02 million$14.02 billionViewN/AView Earnings Details
1/23/2013Q412$1.19$1.27$14.42 billion$14.80 billionViewN/AView Earnings Details
10/25/2012$1.34$1.34ViewN/AView Earnings Details
7/19/2012$1.33$1.38ViewN/AView Earnings Details
4/24/2012$1.30$1.27ViewN/AView Earnings Details
1/25/2012$1.26$1.23ViewN/AView Earnings Details
10/25/2011$1.45$1.45ViewN/AView Earnings Details
7/19/2011$1.46$1.48ViewN/AView Earnings Details
4/19/2011$1.30$1.41ViewN/AView Earnings Details
1/27/2011$1.25$1.14ViewN/AView Earnings Details
10/21/2010Q3 2010$1.20$1.36ViewN/AView Earnings Details
7/15/2010Q2 2010$1.13$1.20ViewN/AView Earnings Details
1/26/2010Q4 2009$1.16$1.01ViewN/AView Earnings Details
10/22/2009Q3 2009$0.95$0.92ViewN/AView Earnings Details
4/23/2009Q1 2009$0.87$0.87ViewN/AView Earnings Details
1/28/2009Q4 2008$0.79$0.66ViewN/AView Earnings Details
10/20/2008Q3 2008$0.99$0.92ViewN/AView Earnings Details
7/17/2008Q2 2008$0.93$0.99ViewN/AView Earnings Details
1/23/2008Q4 2007$0.67$0.41ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Novartis (NYSE:NVS) Earnings Estimates

Current Year EPS Consensus Estimate: $4.79 EPS
Next Year EPS Consensus Estimate: $5.24 EPS

Dividends

Novartis (NYSE:NVS) Dividend Information

Most Recent Dividend:3/3/2017
Annual Dividend:$2.30
Dividend Yield:2.64%
Dividend Growth:-0.50% (3 Year Average)
Payout Ratio:81.85% (Trailing 12 Months of Earnings)
48.02% (Based on This Year's Estimates)
43.89% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Novartis (NYSE:NVS)

Novartis (NYSE:NVS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/27/2017Annual$2.333/1/20173/3/20173/3/2017
2/1/2016Annual$2.342/24/20162/26/20162/26/2016
2/4/2014annual$2.723.48%2/27/20143/3/20143/11/2014
2/11/2013annual$2.533.71%2/26/20132/28/20134/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Novartis (NYSE NVS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.01%
Institutional Ownership Percentage: 10.85%
Insider Trades by Quarter for Novartis (NYSE:NVS)
Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Novartis (NYSE NVS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/5/2017Bioventures Ltd NovartisMajor ShareholderBuy266,667$15.00$4,000,005.00View SEC Filing  
5/11/2016Institutes For Biomed NovartisMajor ShareholderBuy277,777$18.00$4,999,986.00View SEC Filing  
2/17/2016Bioventures Ltd NovartisMajor ShareholderBuy375,000$8.00$3,000,000.00View SEC Filing  
9/22/2014Bioventures Ltd NovartisMajor ShareholderBuy325,000$15.00$4,875,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Novartis (NYSE NVS) News Headlines

Source:
DateHeadline
Novartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering periodNovartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering period
finance.yahoo.com - January 22 at 3:44 PM
Novartis completes tender offer for Advanced Accelerator ... - GlobeNewswire (press release)Novartis completes tender offer for Advanced Accelerator ... - GlobeNewswire (press release)
globenewswire.com - January 22 at 8:15 AM
Head-To-Head Survey: Novartis (NVS) & Cadence Pharmaceuticals (CADX)Head-To-Head Survey: Novartis (NVS) & Cadence Pharmaceuticals (CADX)
www.americanbankingnews.com - January 20 at 5:14 PM
Novartis AG (NVS) Receives Consensus Recommendation of "Hold" from BrokeragesNovartis AG (NVS) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 20 at 3:52 PM
Blog Exposure - FDA Granted Priority Review to Novartis’ Kymriah(TM) for Adults with relapsed/refractory B-cell lymphomaBlog Exposure - FDA Granted Priority Review to Novartis’ Kymriah(TM) for Adults with relapsed/refractory B-cell lymphoma
finance.yahoo.com - January 19 at 5:02 PM
Active-Investors: Blog Exposure - FDA Granted Priority Review to Novartis Kymriah for Adults with relapsed/refractory B-cell lymphomaActive-Investors: Blog Exposure - FDA Granted Priority Review to Novartis' Kymriah for Adults with relapsed/refractory B-cell lymphoma
www.finanznachrichten.de - January 19 at 11:46 AM
Cancer Space Update: Label Expansions, Data Readouts in FocusCancer Space Update: Label Expansions, Data Readouts in Focus
finance.yahoo.com - January 19 at 11:46 AM
Here’s What’s Moving Novartis And Aeterna Zentaris Right NowHere’s What’s Moving Novartis And Aeterna Zentaris Right Now
finance.yahoo.com - January 18 at 11:15 AM
A Look into Amgen’s Collaborations in 2H17A Look into Amgen’s Collaborations in 2H17
finance.yahoo.com - January 18 at 11:15 AM
JPMorgan Chase & Co. Reiterates "Neutral" Rating for Novartis (NVS)JPMorgan Chase & Co. Reiterates "Neutral" Rating for Novartis (NVS)
www.americanbankingnews.com - January 18 at 8:36 AM
Novartiss Kymriah wins speedy reviews in U.S., EuropeNovartis's Kymriah wins speedy reviews in U.S., Europe
finance.yahoo.com - January 17 at 10:13 AM
Vertex Pharmaceuticals Has Robust Late-Stage Research PipelineVertex Pharmaceuticals Has Robust Late-Stage Research Pipeline
finance.yahoo.com - January 17 at 10:13 AM
Vertex Pharmaceuticals to Target 90% of Cystic Fibrosis PatientsVertex Pharmaceuticals to Target 90% of Cystic Fibrosis Patients
finance.yahoo.com - January 17 at 10:13 AM
Novartis (NVS) Scheduled to Post Quarterly Earnings on WednesdayNovartis (NVS) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - January 17 at 3:26 AM
Why is Puma (PBYI) Stock Up More than 150% in a Years Time?Why is Puma (PBYI) Stock Up More than 150% in a Year's Time?
www.zacks.com - January 16 at 10:18 AM
UBS Group Reaffirms "Neutral" Rating for Novartis (NVS)UBS Group Reaffirms "Neutral" Rating for Novartis (NVS)
www.americanbankingnews.com - January 15 at 11:02 AM
Novartis becomes latest big-name collaborator for Chapel Hill companyNovartis becomes latest big-name collaborator for Chapel Hill company
finance.yahoo.com - January 10 at 4:37 PM
Ignyta and Its Key Risks in 2018Ignyta and Its Key Risks in 2018
finance.yahoo.com - January 10 at 10:23 AM
Novartis Starts Trial on Psoriasis Drug Cosentyx BiosoimilarNovartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar
finance.yahoo.com - January 10 at 10:23 AM
Novartis AG (NVS) to Post FY2022 Earnings of $8.24 Per Share, Jefferies Group ForecastsNovartis AG (NVS) to Post FY2022 Earnings of $8.24 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - January 8 at 8:40 PM
Novartis AG (NVS) Sees Large Decrease in Short InterestNovartis AG (NVS) Sees Large Decrease in Short Interest
www.americanbankingnews.com - January 5 at 2:10 AM
Novartis Kisqali Gets FDA Breakthrough Therapy DesignationNovartis Kisqali Gets FDA Breakthrough Therapy Designation
www.finanznachrichten.de - January 3 at 9:25 AM
Novartis (NVS) Stock Rating Lowered by Zacks Investment ResearchNovartis (NVS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 2 at 12:00 PM
Swiss stocks - Factors to watch on Dec 28Swiss stocks - Factors to watch on Dec 28
finance.yahoo.com - December 28 at 8:52 AM
BRIEF-China Pioneer Pharma Enters Agreement For Sale Of Ophthalmic Pharmaceutical ProductsBRIEF-China Pioneer Pharma Enters Agreement For Sale Of Ophthalmic Pharmaceutical Products
finance.yahoo.com - December 28 at 8:52 AM
BRIEF-Luye Pharma Group‍ Announces Update on Patent Litigation Regarding Rivastigmine 1 Day PatchBRIEF-Luye Pharma Group‍ Announces Update on Patent Litigation Regarding Rivastigmine 1 Day Patch
finance.yahoo.com - December 28 at 12:12 AM
Gadflys 2017 Toast to the DepartedGadfly's 2017 Toast to the Departed
finance.yahoo.com - December 27 at 1:06 PM
Novartis (NVS) Earns Neutral Rating from Nord/LBNovartis (NVS) Earns Neutral Rating from Nord/LB
www.americanbankingnews.com - December 27 at 8:48 AM
Novartis AG (NVS) Receives Average Rating of "Hold" from AnalystsNovartis AG (NVS) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - December 26 at 4:39 PM
Novartis AG (NVS) Given Consensus Rating of "Hold" by AnalystsNovartis AG (NVS) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - December 26 at 4:39 PM
Five Milestones Of 2017 In The War On CancerFive Milestones Of 2017 In The War On Cancer
finance.yahoo.com - December 21 at 10:17 AM
Novartis AG (NVS) Short Interest Up 41.2% in NovemberNovartis AG (NVS) Short Interest Up 41.2% in November
www.americanbankingnews.com - December 19 at 4:22 AM
Novartis Gelenya a Breakthrough Therapy for pediatric MS - Seeking AlphaNovartis' Gelenya a Breakthrough Therapy for pediatric MS - Seeking Alpha
seekingalpha.com - December 18 at 4:35 PM
ETFs with exposure to Novartis AG : December 15, 2017ETFs with exposure to Novartis AG : December 15, 2017
finance.yahoo.com - December 16 at 10:20 AM
ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More - BenzingaASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More - Benzinga
www.benzinga.com - December 13 at 4:47 PM
Health Care Sector Update for 12/13/2017: NVS,IOVA,RSLS - NasdaqHealth Care Sector Update for 12/13/2017: NVS,IOVA,RSLS - Nasdaq
www.nasdaq.com - December 13 at 4:47 PM
Novartis generics arm says may sell or end some productsNovartis generics arm says may sell or end some products
finance.yahoo.com - December 13 at 10:40 AM
Form 8-K PROTEOSTASIS THERAPEUTIC For: Dec 05Form 8-K PROTEOSTASIS THERAPEUTIC For: Dec 05
www.streetinsider.com - December 12 at 4:55 PM
Novartis Reports Updated Results from Kymriahs JULIET Study - NasdaqNovartis Reports Updated Results from Kymriah's JULIET Study - Nasdaq
www.nasdaq.com - December 12 at 10:45 AM
These defensive stocks make the cut as one of Morgan Stanley’s key picks for 2018These defensive stocks make the cut as one of Morgan Stanley’s key picks for 2018
finance.yahoo.com - December 11 at 4:47 PM
Here's Why Bluebird Bio (BLUE) Stock Skyrocketed TodayHere's Why Bluebird Bio (BLUE) Stock Skyrocketed Today
finance.yahoo.com - December 11 at 4:47 PM
Novartis CAR-T therapy leads to durable response in lymphoma studyNovartis CAR-T therapy leads to durable response in lymphoma study
finance.yahoo.com - December 10 at 4:48 PM
Novartis AG (NVS) a Buy on High-Level Quant Score - Investorplace.comNovartis AG (NVS) a Buy on High-Level Quant Score - Investorplace.com
www.investorplace.com - December 8 at 4:33 PM
Pfizer Reports Updated Data from Phase III Study on IbrancePfizer Reports Updated Data from Phase III Study on Ibrance
finance.yahoo.com - December 7 at 4:54 PM
Novartis Commences Cash Tender Offer To Buy Advanced Accelerator ApplicationsNovartis Commences Cash Tender Offer To Buy Advanced Accelerator Applications
www.nasdaq.com - December 7 at 10:41 AM
In Young Women With Metastatic Breast Cancer, Kisqali Delays Tumor Growth And Relieves SymptomsIn Young Women With Metastatic Breast Cancer, Kisqali Delays Tumor Growth And Relieves Symptoms
finance.yahoo.com - December 7 at 10:41 AM
Novartis (NVS) Rating Lowered to Underperform at Bank of AmericaNovartis (NVS) Rating Lowered to Underperform at Bank of America
www.americanbankingnews.com - December 6 at 9:20 PM
Advanced Accelerator Applications (AAAP) Board of Directors Backs $3.9 Billion All Cash Tender Offer by Novartis (NVS) - StreetInsider.comAdvanced Accelerator Applications (AAAP) Board of Directors Backs $3.9 Billion All Cash Tender Offer by Novartis (NVS) - StreetInsider.com
www.streetinsider.com - December 6 at 10:35 AM
Advanced Accelerator Applications Board of Directors Recommends $3.9 Billion All Cash Tender Offer by NovartisAdvanced Accelerator Applications Board of Directors Recommends $3.9 Billion All Cash Tender Offer by Novartis
finance.yahoo.com - December 5 at 4:33 PM
Behind Novartis’s Developments as of November 2017Behind Novartis’s Developments as of November 2017
finance.yahoo.com - December 4 at 4:37 PM

SEC Filings

Novartis (NYSE:NVS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Novartis (NYSE:NVS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Novartis (NYSE NVS) Stock Chart for Tuesday, January, 23, 2018

Loading chart…

This page was last updated on 1/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.